ConjuChem Provides Development Update ( - Phase II PC-DAC(TM):Exendin-4 ...)

ConjuChem Provides Development Update

Date:11/5/2008

- Phase II PC-DAC(TM):Exendin-4 Data in December -

- PC-Insulin Preclinical Study Results -

MONTREAL, Nov. 5 /PRNewswire-FirstCall/ - ConjuChem Biotechnologies Inc. (TSX:CJB) announced today that dosing is complete for its Phase II clinical trial of PC-DAC(TM):Exendin-4. This Phase II trial was a randomized, double-blind, placebo-controlled, multiple dose study that evaluated the efficacy and safety of three months of weekly injections of PC-DAC(TM):Exendin-4 in patients with Type 2 diabetes not adequately controlled by metformin monotherapy. The trial enrolled approximately 120 evaluable patients randomized to one of three parallel treatment groups: a 1.5mg fixed-dose weekly cohort; a 1.5mg weekly dose titrating to 2mg at the 5th week cohort; and a placebo group. Top line data from the trial will be announced in December, 2008.

The Company also announced the results of a preclinical study evaluating the pharmacodynamics of its PC-Insulin versus Lantus(R) (insulin glargine (rDNA) injection) after repeated daily subcutaneous administration in streptozotocin-induced diabetic rats. A similar reduction in blood glucose was observed with both compounds at 2, 6, and 8 hours after each dose but glucose levels at 24 hours were only normalized in animals treated with PC-Insulin. In addition to a superior control of blood glucose, PC-Insulin was more effective in normalizing physiologic parameters such as water intake in the diabetic rats.

Commenting on the progress of the PC-Insulin program, Dr. Thomas Ulich, Executive Vice president, stated, "We are very encouraged with the emerging profile of PC-Insulin and believe it can achieve our objective of a more peakless basal insulin with a longer duration of activity." Results of this study will be submitted for the 2009 American Diabetes Association meeting. The Company plans to submit an IND in mid-2009.

About PC-DAC(TM):Exendin-4

Exendin-4, like Glucagon-like peptide-1 (G
'/>"/>

0

GOOD

Page: 1 2 3
Related biology technology :

1. BioCryst Reports Third Quarter 2008 Financial Results and Provides Corporate Update
2. Memory Pharmaceuticals Provides Update on NASDAQ Listing Status
3. Golub Capital Provides Debt Financing to Support the Acquisition of DNA Diagnostics Center, Inc. by MTS Health Investors, LLC
4. China Biologic Products Provides Preliminary Guidance for 2009 of Revenues of $90 to $100 Million and Net Income of $18 to 22 Million
5. Boston Scientific Provides Comments Reinforcing Strength of Its Balance Sheet
6. Boston Scientific Provides Update on Involuntary Selling of Its Stock by Co-Founders
7. The Plasmodium vivax genome provides new routes and challenges in the global fight against malaria
8. Nventa Provides Corporate Update and Advancement Plans for HspE7, Hsp 6/11 and Poly-ICR
9. Pressure BioSciences, Inc. Provides Corporate Update
10. Cell Therapeutics Provides Details on Investor & Media Day to be Held in Milan, Italy on Friday, October 3, 2008
11. FDA Meeting Provides Green Light for Cell Therapeutics Submission of Supplemental Filing for Zevalin(R) Label Expansion

Post Your Comments:

ConjuChem Provides Development Update( - Phase II PC-DAC(TM):Exendin-4 ...)